Table 1.
Patient characteristics
| Age | Sex | WHO grade | Pathology | MGMTa | IDH1b | P53 | 1p/19q | Ki-67 L.I. | EGFRg | No. of implanted mice | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case #1 | 24 | M | IV | GBMc | Methylation | Wild type | Wild type | Intact | 5 % | 0 | 3 |
| Case #2 | 61 | M | IV | GBMc | Unmethylation | Wild type | 5 % | LOH/intact | Focal 20–30 % and overall 5 % | 3+ | 3 |
| Case #3 | 24 | M | IV | GBMc | Unmethylation | Wild type | 80–90 % | Intact | 50 % | 2–3+ | 3 |
| Case #4 | 50 | M | IV | GBMc | Methylation | Mutation | NA | NA | NA | NA | 3 |
| Case #5 | 62 | F | IV | GBMc | Methylation | Wild type | Wild type | Intact | 5–6 % | 3+ | 4 |
| Case #6 | 11 | M | IV | GBMc | Unmethylation | Wild type | 50–60 % | Intact | 70–80 % | 0 | 3 |
| Case #7 | 26 | M | IV | GBMc | Unmethylation | Wild type | 50–60 % | LOHf | 40–50 % | 2–3+ | 3 |
| Case #8 | 1.3 | M | IV | PNETd | NAe | NA | NA | NA | 50–60 % | NA | 3 |
a O(6)-methylguanine methyltransferase
b Isocitrate dehydrogenase 1
c Glioblastoma
d Primitive neuroectodermal tumor
e Non-available
f Loss of heterozygosity
g Epidermal growth factor receptor amplification